Accessibility Menu
 
An2 Therapeutics logo

An2 Therapeutics

(NASDAQ) ANTX

Current Price$3.67
Market Cap$131.54M
Since IPO (2022)-76%
5 YearN/A
1 Year+154%
1 Month+245%

An2 Therapeutics Financials at a Glance

Market Cap

$131.54M

Revenue (TTM)

$0.00

Net Income (TTM)

$35.17M

EPS (TTM)

$-1.16

P/E Ratio

-3.14

Dividend

$0.00

Beta (Volatility)

0.84 (Low)

Price

$3.67

Volume

313

Open

$3.66

Previous Close

$3.66

Daily Range

$3.56 - $4.01

52-Week Range

$1.00 - $6.91

ANTX News

No articles available.

ANTX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About An2 Therapeutics

Industry

Pharmaceuticals

Employees

21

CEO

Eric Easom, MBA

Headquarters

Menlo Park, CA 94027, US

ANTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-52%

Return on Capital

-72%

Return on Assets

-57%

Earnings Yield

-31.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$131.54M

Shares Outstanding

35.94M

Volume

313

Short Interest

0.00%

Avg. Volume

1.35M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$38.11M

EBITDA

$38.11M

Operating Cash Flow

$29.83M

Capital Expenditure

$0.00

Free Cash Flow

$29.83M

Cash & ST Invst.

$58.00M

Total Debt

$0.00

An2 Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$131.54M

N/A

Market Cap/Employee

$5.98M

N/A

Employees

22

N/A

Net Income

$8.71M

-15.8%

EBITDA

$10.00M

N/A

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$58.00M

-30.6%

Accounts Receivable

$900.00K

+200.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-56.78%

N/A

Return on Invested Capital

-71.59%

N/A

Free Cash Flow

$5.24M

+0.7%

Operating Cash Flow

$5.24M

+0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QTTBQ32 Bio Inc.
$7.25+1.54%
VRCAVerrica Pharmaceuticals Inc.
$4.38-0.23%
SABSSAB Biotherapeutics, Inc.
$3.85+0.52%
IBIOiBio, Inc.
$1.76+1.15%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.56-0.06%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$87.42+0.06%
IBITiShares Bitcoin Trust
$37.40-0.04%

Questions About ANTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.